


Identification of tumor-associated pathways in *MEN1/DAXX/ATRX* mutated Pancreatic Neuroendocrine Tumors (PanNETs)

Di Domenico A.⁺, Pipinikas CP.[‡], Maire R.⁺, Bräutigam K.⁺, Thirlwell C.^{‡§}, Perren A.⁺ and Marinoni I.⁺

⁺ Institute of Pathology, University of Bern, Bern (CH); [‡] UCL Cancer Institute, London (UK); [§] University of Exeter, College of Medicine and Health, Exeter (UK)

Background

- The most commonly mutated genes in PanNETs are *MEN1*, *DAXX* and *ATRX*.
- Menin, DAXX and ATRX are involved in chromatin remodeling and epigenetic regulation.
- Cell of origin, pathways and mechanism of progression associated with *DAXX/ATRX* mutations are still unclear.




<i>MEN1</i>	41%
<i>DAXX, ATRX</i>	32%

Aims and Experimental Setup

- Does epigenetic reveal cell of origin of PanNETs? (section 1)
- Do epigenetic profiles correspond to a specific genetic background? (section 1)
- Do epigenetic signatures show clinical relevance? (section 1)
- Do epigenetic signatures overlap with already published gene expression PanNET subgroups? (section 2 and 3)
- Which are the main dysregulated pathways in *DAXX/ATRX/MEN1* mutated tumors? (section 4)

DNA methylation (Illumina, 450K arrays) and gene expression (RNAseq) signatures of PanNETs and putative α - β -cells of origin have been analyzed to answer these questions

1. DNA methylation profiles of PanNETs reveal at least 2 cells of origin and 3 PanNET epigenetic subgroups with clinical relevance



α -like: high similarity to normal α -cells; mainly *MEN1* mutated



β -like: high similarity to normal β -cells; mainly *MEN1/DAXX/ATRX* wild type.

Intermediate: intermediate similarity to α - or β -cells; higher values are shown for α -cell similarity; subgroup enriched for tumors with *MEN1/DAXX/ATRX* (intermediate-ADM) mutations.

[click here to be directed to the publication](#)

DNA methylation signatures of the epigenetic subtypes show relevance in relapse prognosis and separate intermediate tumors in:


- PanNETs with *MEN1/DAXX/ATRX* mutations (intermediate-ADM)
- PanNETs *MEN1/DAXX/ATRX* wild type (intermediate-WT)



[click here to be directed to the publication](#)


2. Gene expression signatures partially recapitulate the epigenetic groups.

PCA of the top 500 most variable expressed genes





3. A subset of Intermediate-ADM PanNETs share the hypoxia signature (group 3) described by Scarpa *et al.*

Consensus clustering of the top 2000 most variable expressed genes



Intermediate-ADM-non hypoxic Intermediate-ADM-hypoxic

4. GSEA for Intermediate-ADM-hypoxic and Intermediate-ADM-non hypoxic PanNETs shows new distinct oncogenic pathways *DAXX/ATRX* dependent



Conclusion

- DNA methylation signatures define PanNETs with:
 - Distinct cell of origin
 - Specific genetic background
 - Different clinical outcome
- Gene expression signatures partially overlap with the epigenetic subgroups
- Intermediate-ADM PanNETs show transcriptional heterogeneity.
- New oncogenic pathways for intermediate-ADM tumors could be identified.

Contacts

Annunziata Di Domenico, PhD: annunziata.didomenico@pathology.unibe.ch
 Iliaria Marinoni, PhD: iliana.marinoni@pathology.unibe.ch
 Aurel Perren, Prof. Dr. med: aurel.perren@pathology.unibe.ch